Collectively this underscores the need for better molecular classification [19,23,41,45], and ER+/HER2- breast tumors may be the “canary in the coal mine” pointing us to a more effective predictive model: a combination of receptor assays and DRC. The gene discussed is ESR1; the disease is breast neoplasm.